Analyst Price Targets — CRL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 11:42 am | — | Piper Sandler | $300.00 | $269.64 | StreetInsider | Charles River Labs (CRL) PT Raised to $300 at TD Cowen |
| August 10, 2026 11:13 am | — | Mizuho Securities | $264.00 | $267.49 | TheFly | Charles River price target raised to $264 from $230 at Mizuho |
| August 7, 2026 1:29 pm | — | Morgan Stanley | $300.00 | $264.05 | TheFly | Charles River price target raised to $300 from $260 at Morgan Stanley |
| August 6, 2026 1:19 pm | — | Robert W. Baird | $291.00 | $258.93 | TheFly | Charles River price target raised to $291 from $255 at Baird |
| August 6, 2026 10:44 am | — | RBC Capital | $282.00 | $260.72 | TheFly | Charles River price target raised to $282 from $215 at RBC Capital |
| August 5, 2026 7:17 pm | — | Barclays | $300.00 | $260.72 | TheFly | Charles River price target raised to $300 from $220 at Barclays |
| July 13, 2026 11:43 am | — | Mizuho Securities | $230.00 | $233.41 | TheFly | Charles River price target raised to $230 from $192 at Mizuho |
| July 9, 2026 10:57 am | — | Morgan Stanley | $260.00 | $223.96 | TheFly | Charles River price target raised to $260 from $220 at Morgan Stanley |
| July 1, 2026 7:56 am | — | BNP Paribas | $250.00 | $226.79 | StreetInsider | Charles River Labs (CRL) PT Raised to $250 at Argus |
| July 1, 2026 7:56 am | — | Bernstein | $250.00 | $226.79 | StreetInsider | Charles River Labs (CRL) PT Raised to $250 at Argus |
Latest News for CRL
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Charles River Laboratories International (NYSE: CRL - Get Free Report) and IB Acquisition (NASDAQ: IBAC - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares
According to prediction markets, final passage of the Clarity Act is not likely to happen until mid-2027 at the earliest. If the Clarity Act stalls out in Congress, the crypto industry will need to rely on favorable rule making from the likes of the SEC, CFTC, and OCC.
Great Lakes Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,026 shares of the medical research company's stock, valued at approximately $459,000. A
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRL.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.